Bio-Rad Laboratories, Inc. (BIO)
Healthcare • Medical Devices
StockNYSEUnited StatesUS0905722072
368.14 USD
-0.63% today Updated 13 Nov 2026 15:34
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Bio-Rad Laboratories, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:34. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
11 Feb 2027
in 90 days · 16:00 · estimate 2.83
Last results
2.65 vs 2.23 estimated
04 Nov 2026 · Beat +19.1%
Beat the estimate
9 of 12
2 missed · 1 in line · 2 beats in a row
Average surprise
+25.6%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 16:00 | 2.83 | — | — | Upcoming |
| 04 Nov 2026 16:00 | 2.23 | 2.65 | +19.1% | Beat |
| 04 Aug 2026 16:00 | 1.75 | 2.62 | +50.1% | Beat |
| 30 Apr 2026 16:00 | 1.99 | 1.89 | -4.8% | Miss |
| 12 Feb 2026 16:00 | 2.70 | 2.51 | -7.0% | Miss |
| 29 Oct 2025 16:00 | 1.93 | 2.26 | +17.0% | Beat |
| 31 Jul 2025 16:00 | 1.75 | 2.61 | +49.5% | Beat |
| 01 May 2025 16:00 | 1.78 | 2.54 | +42.5% | Beat |
| 13 Feb 2025 16:00 | 2.88 | 2.90 | +0.6% | In line |
| 30 Oct 2024 16:00 | 1.18 | 2.01 | +70.8% | Beat |
| 01 Aug 2024 16:00 | 2.02 | 3.11 | +54.3% | Beat |
| 07 May 2024 16:00 | 2.14 | 2.29 | +7.1% | Beat |
| 15 Feb 2024 16:00 | 2.87 | 3.10 | +8.2% | Beat |
| 26 Oct 2023 16:00 | 2.81 | 2.33 | -17.2% | Miss |
| 03 Aug 2023 16:00 | 2.68 | 3.00 | +12.0% | Beat |
| 04 May 2023 16:00 | 3.48 | 3.34 | -3.9% | Miss |
| 16 Feb 2023 16:00 | 3.44 | 3.31 | -3.8% | Miss |
| 27 Oct 2022 16:00 | 2.77 | 2.60 | -6.0% | Miss |
| 28 Jul 2022 16:00 | 2.77 | 3.38 | +21.9% | Beat |
| 28 Apr 2022 16:00 | 3.23 | 4.94 | +53.2% | Beat |
| 10 Feb 2022 16:00 | 2.87 | 3.21 | +11.8% | Beat |
| 28 Oct 2021 16:00 | 2.48 | 3.71 | +49.6% | Beat |
| 29 Jul 2021 16:00 | 2.70 | 3.54 | +31.0% | Beat |
| 29 Apr 2021 16:00 | 2.94 | 5.21 | +77.2% | Beat |
| 11 Feb 2021 16:00 | 3.32 | 4.01 | +20.9% | Beat |
| 29 Oct 2020 16:00 | 1.82 | 3.00 | +64.9% | Beat |
| 30 Jul 2020 16:00 | 1.15 | 1.61 | +40.3% | Beat |
| 06 May 2020 17:00 | 1.57 | 1.91 | +22.0% | Beat |
| 13 Feb 2020 16:00 | 2.45 | 2.32 | -5.1% | Miss |
| 31 Oct 2019 16:00 | 1.41 | 1.61 | +14.6% | Beat |
| 01 Aug 2019 16:00 | 1.34 | 1.57 | +17.1% | Beat |
| 08 May 2019 16:00 | 1.09 | 1.65 | +51.0% | Beat |
| 28 Feb 2019 16:00 | 1.73 | 2.13 | +22.9% | Beat |
| 01 Nov 2018 16:00 | 1.14 | 0.91 | -20.0% | Miss |
| 07 Aug 2018 16:00 | 1.28 | 1.64 | +28.1% | Beat |
| 08 May 2018 16:00 | 1.22 | 1.00 | -17.8% | Miss |
| 27 Feb 2018 16:00 | 1.25 | 2.32 | +86.1% | Beat |
| 02 Nov 2017 16:00 | 0.60 | 0.91 | +52.9% | Beat |
| 03 Aug 2017 16:00 | 0.68 | 0.17 | -75.1% | Miss |
| 04 May 2017 16:00 | 0.27 | 0.41 | +54.7% | Beat |
| 23 Feb 2017 16:00 | 1.09 | 0.78 | -28.3% | Miss |
| 01 Nov 2016 16:00 | 0.51 | 0.62 | +21.6% | Beat |
| 03 Aug 2016 16:00 | 1.13 | 0.61 | -46.0% | Miss |
| 05 May 2016 16:00 | 0.60 | 0.42 | -30.0% | Miss |
| 25 Feb 2016 16:00 | 1.40 | 1.68 | +20.0% | Beat |
| 03 Nov 2015 16:00 | 0.54 | 0.87 | +62.8% | Beat |
| 06 Aug 2015 16:00 | 0.78 | 0.97 | +25.2% | Beat |
| 05 May 2015 16:00 | 0.33 | 0.61 | +84.9% | Beat |
| 26 Feb 2015 16:00 | 1.18 | 1.88 | +58.9% | Beat |
| 04 Nov 2014 16:00 | 0.86 | 0.81 | -5.8% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 2.6B | +0.7% | 759.9M | 29.4% | 27.85 | +142.6% | 374.6M |
| 2024 | 2.6B | -3.9% | -1.8B | -71.9% | -65.36 | -199.5% | 266.2M |
| 2023 | 2.7B | -4.7% | -637.3M | -23.9% | -21.82 | +82.1% | 218.2M |
| 2022 | 2.8B | — | -3.6B | -129.5% | -121.79 | — | 80.1M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 385.38 | 394.73 | 365.77 | 368.14 | -3.52% | 1,166,979 | |
| 02 Nov 2026 – 06 Nov 2026 | 374.79 | 384.62 | 352.09 | 381.57 | +2.52% | 1,415,100 | |
| 26 Oct 2026 – 30 Oct 2026 | 371.80 | 390.16 | 368.45 | 372.18 | +0.60% | 1,113,000 | |
| 19 Oct 2026 – 23 Oct 2026 | 355.30 | 371.31 | 347.29 | 369.95 | +4.59% | 1,189,300 | |
| 12 Oct 2026 – 16 Oct 2026 | 369.85 | 371.07 | 350.77 | 353.70 | -3.40% | 1,066,600 | |
| 05 Oct 2026 – 09 Oct 2026 | 368.07 | 390.00 | 353.97 | 366.16 | -0.81% | 1,144,500 | |
| 28 Sep 2026 – 02 Oct 2026 | 376.98 | 383.95 | 353.30 | 369.14 | -3.11% | 1,251,100 | |
| 21 Sep 2026 – 25 Sep 2026 | 381.58 | 389.38 | 373.47 | 381.00 | +1.22% | 1,491,200 | |
| 14 Sep 2026 – 18 Sep 2026 | 365.66 | 385.71 | 365.66 | 376.41 | +1.92% | 1,603,800 | |
| 08 Sep 2026 – 11 Sep 2026 | 390.73 | 390.73 | 368.56 | 369.32 | -4.35% | 995,000 | |
| 253 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate (opens in a new tab) 11 Nov 2026 14:21
- Single-Cell Analysis - Global Strategic Business Report 2026: Capitalize on 20.4% CAGR as Illumina, Thermo Fisher Scientific, Bio-Rad and Agilent Battle for Shares in the $26.1 Billion Market by 2032 (opens in a new tab) 11 Nov 2026 14:18
- Molecular Cytogenetics - Global Strategic Business Report: Capitalize on 8.8% CAGR to US$3.5 Billion by 2030; Outmaneuver Abbott, Agilent, Bio-Rad, Illumina and Roche Amid Tariff Shifts (opens in a new tab) 11 Nov 2026 14:13
- Capillary Electrophoresis - Global Strategic Business Report: Secure Share of the $1.1 Billion Market by 2032 as Agilent, Bio-Rad, Danaher and Thermo Fisher Accelerate CE-MS Innovation (opens in a new tab) 10 Nov 2026 15:11
- Nucleic Acid Isolation and Purification - Global Strategic Business Report: Capture the $3.9 Billion Revenue Surge by 2030 as Thermo Fisher, Qiagen, Danaher, Illumina, and Bio-Rad Battle for Share (opens in a new tab) 10 Nov 2026 15:02
- Gene Amplification Technologies - Global Strategic Business Report: Capture $4.4B in New Revenue by 2030 as Abbott, Bio-Rad, bioMerieux, Cepheid and Becton Dickinson Battle for Share (opens in a new tab) 10 Nov 2026 14:20
- Bio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 12:41
- Why Is Bio Rad Laboratories (BIO) Drawing Elliott’s Attention Now? (opens in a new tab) Simply Wall St. · 10 Nov 2026 12:11
- How Investors Are Reacting To Bio Rad (BIO) International Revenue Surprise (opens in a new tab) Simply Wall St. · 10 Nov 2026 11:08
- Why Bio-Rad (BIO) International Revenue Trends Deserve Your Attention (opens in a new tab) Zacks · 09 Nov 2026 13:15
- Is Bio-Rad Laboratories, Inc. (BIO) an Activist Investor Target With Significant Hidden Value (opens in a new tab) Insider Monkey · 07 Nov 2026 12:22
- Bio-Rad (BIO) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 15:45
- RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440 (opens in a new tab) Benzinga · 05 Nov 2026 14:41
- Bio-Rad Laboratories, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Nov 2026 13:30
- Bio-Rad Laboratories Inc (BIO) (Q3 2026) Earnings Call Highlights: Return to Currency-Neutral ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 13:08
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 370.48 USD
- Market cap
- 10.0B
- Exchange
- NYSE
- Country
- United States
- Sector
- Healthcare
- Industry
- Medical Devices
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow BIO and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.